GlaxoSmithKline and Innoviva seek to broaden Trelegy Ellipta indication


GlaxoSmithKline, along with its partner Innoviva, announced the filing of a supplemental New Drug Application with the US Food and Drug Administration on Thursday, for the use of Trelegy Ellipta . The FTSE 100 drugmaker said the application was for an expanded indication, for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic obstructive pulmonary disease.



from Biotech News